Ortega SMA, Osnaya OML, Rosas BJV

Language: Spanish
References: 18
Page: 26-33
PDF size: 134.03 Kb.

ABSTRACT

Leukemias are a heterogeneous group of illness with bone marrow, blood and other tissue infiltration; characterized by neoplastic hematopoietic cells, and is due to somatic mutation of principal cell; it is classified in acute and chronic and lymphoid or myeloid according to cellular linage. This paper reviews the basic points about lymphoblastic leukemia management. This leukemia has an acute presentation due to blasts in blood. In 2000 Mexico reported 1,926 new cases and 3,301 deaths. Its etiology is multifactorial: genetic, hereditary and environmental factors. Clinically, this pathology courses with asthenia, fever, anemia, bleeding, infections, bone pain, hepatosplenomegaly, and lymphadenopathy. Its diagnosis is based on clinic, hemogram, bone marrow aspiration, immunophenotype and cariotype. The presence of Philadelphia chromosome is a bad prognostic factor, and most of cases can be fatal.

REFERENCES

1. Beutler E, Lichtman M, Coller B, Kipps T, et al. Williams Hematology. 6th ed. New York: McGraw-Hill, 2001;pp:1141-61.

2. Fauci A, Braunwald E, Isselbacher K, Wilson J, y col. Harrison. Principios de medicina interna. 4a ed. Madrid: McGraw-Hill Interamericana, 1998;pp:781-92.

3. Dirección general de epidemiología. En: Compendio de cáncer. Mortalidad-morbilidad. México: Secretaría de Salud, 2000.

4. Ruiz Argüelles GJ. Fundamentos de hematología. 2a ed. México: Panamericana, 1998.

5. Mustafa M, Winick M, Margraf L. Epstein-Barr virus lymphoprolyferative disorder in children with leukemia: case report and review of the literature. J Pediatr Hematol Oncol 1997;19(1):77-81.

6. Bennet JM, Catovsky D, Daniel MT, Flandrin G, et al. Proposals for the classification of the acute leukemias. French-American- British (FAB) co-operative group. Br J Hematol 1976;33:451.

7. Stock W, Treatment of adult acute lymphoblastic leukemia: riskadapted strategies. In: Nancy Berliner, editor. Hematology. 1st ed. Washington: American Society of Hematology, 1999;p:87.

8. Kantarjian HM, O’Brien S, Smith TL, Cortes J, et al. Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocitic leukemia. J Clinic Oncol 2000;18(3):547.

9. Larson RA, Dodge RK, Burns CP. A five-drug remission. Induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia. Cancer and leukemia group B study. Blood 1995;85:2025.

10. Hoelzer D, Thiel E, Ludwig W. The German multicentre trials for treatmen of acute lymphoblastic leukemia in adults. The german adult ALL study group. Leukemia 1992;6(2):175.

11. Gaynon PS, Carrel AL. Glycocorticosteroid terapy in childhood acute lymphoblastic leukemia. Adv Exp Med Biol 1999;457:593.

12. Cetin M, Hicsonmez G, Tuncer AM, Kansu E, et al. The effect of short course high-dose corticosteroid therapy on peripheral blood CD34+ progenitor cells in children with acute leukemia. Exp Hematol 1996;24(10):1191.

13. Marcus RE, Catowsky D, Johnson SA. Adult acute lymphoblastic leukemia: a study of prognostic features and response to treatment over a ten year period. Br J Cancer 1986;53:175.

14. Chessells JM, Hall E, Prentice HG. The impact of age of outcome in lymphoblastic leukemia; MRC UKALL X and XA compared: a repod of the MRC pediatric and adult parties. Leukemia 1998;12:469.

15. Hoelzer D, Thiel E, Loffler H, Buchener T, et al. Prognostic factors in a multicenter study for treatment of acute lymphoblastic leukemia in adults. Blood 1988;71:123.

16. Lazarus HM, Rowe JM. Bone marrow transplantation for acute lymphoblastic leukemia. Med Oncol 1994;11(2):75.

17. Fiere D, Sebbart C, Reiffers J. Comparation of ailogenic transplantation, autologous transplantation, and chemoterapy as post induction treatment in adult acute lymphoblastic leukemia, long term report of the French group of treatment of adult ALL. Proc Am Soc Clin Oncol 1998;17:14.

18. Miyamura K, Tanimoto M, Morishuma M. Detection of Philadelphia cromosoma positive acute lymphoblastic leukemia by polymerase chain reaction: possible eradication of minimal residual disease by marrow transplantation. Blood 1992;79:1366.